11-03-2025 | Breast Cancer | Review Article
Head-to-Head comparison of [18F]FES and [18F]FDG PET/CT in breast cancer patients: has a new era come?
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference World Health Organization. Breast Cancer.
World Health Organization. Breast Cancer.
2.
go back to reference Groheux D. Breast cancer systemic staging (Comparison of computed tomography, bone scan, and 18F-Fluorodeoxyglucose PET/Computed Tomography). PET Clin. 2023;18:503–15. https://doi.org/10.1016/j.cpet.2023.04.006.CrossRefPubMed
Groheux D. Breast cancer systemic staging (Comparison of computed tomography, bone scan, and 18F-Fluorodeoxyglucose PET/Computed Tomography). PET Clin. 2023;18:503–15. https://doi.org/10.1016/j.cpet.2023.04.006.CrossRefPubMed
3.
go back to reference Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011;18:3160–3. https://doi.org/10.1245/s10434-011-1919-5.CrossRefPubMed
Croshaw R, Shapiro-Wright H, Svensson E, Erb K, Julian T. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients. Ann Surg Oncol. 2011;18:3160–3. https://doi.org/10.1245/s10434-011-1919-5.CrossRefPubMed
4.
go back to reference Ulaner GA, Vaz SC. Women’s health update: growing role of PET for patients with breast cancer. Semin Nucl Med. 2024;54:247–55. https://doi.org/10.1053/j.semnuclmed.2024.01.007.CrossRefPubMed
Ulaner GA, Vaz SC. Women’s health update: growing role of PET for patients with breast cancer. Semin Nucl Med. 2024;54:247–55. https://doi.org/10.1053/j.semnuclmed.2024.01.007.CrossRefPubMed
5.
go back to reference Groheux D. FDG-PET/CT for primary staging and detection of recurrence of breast cancer. Semin Nucl Med. 2022;52:508–19. https://doi.org/10.1053/j.semnuclmed.2022.05.001.CrossRefPubMed
Groheux D. FDG-PET/CT for primary staging and detection of recurrence of breast cancer. Semin Nucl Med. 2022;52:508–19. https://doi.org/10.1053/j.semnuclmed.2022.05.001.CrossRefPubMed
6.
go back to reference Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, Bidard F-C, Richard F, Yang WW, Steele RE, et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann Oncol. 2022;33:769–85. https://doi.org/10.1016/j.annonc.2022.05.006.CrossRefPubMed
Van Baelen K, Geukens T, Maetens M, Tjan-Heijnen V, Lord CJ, Linn S, Bidard F-C, Richard F, Yang WW, Steele RE, et al. Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancer. Ann Oncol. 2022;33:769–85. https://doi.org/10.1016/j.annonc.2022.05.006.CrossRefPubMed
7.
go back to reference Corso G, Fusco N, Guerini-Rocco E, Leonardi MC, Criscitiello C, Zagami P, Nicolò E, Mazzarol G, La Vecchia C, Pesapane F, et al. Invasive lobular breast cancer: focus on prevention, genetics, diagnosis, and treatment. Semin Oncol. 2024;51:106–22. https://doi.org/10.1053/j.seminoncol.2024.05.001.CrossRefPubMed
Corso G, Fusco N, Guerini-Rocco E, Leonardi MC, Criscitiello C, Zagami P, Nicolò E, Mazzarol G, La Vecchia C, Pesapane F, et al. Invasive lobular breast cancer: focus on prevention, genetics, diagnosis, and treatment. Semin Oncol. 2024;51:106–22. https://doi.org/10.1053/j.seminoncol.2024.05.001.CrossRefPubMed
8.
go back to reference Lloyd MR, Jhaveri K, Kalinsky K, Bardia A, Wander SA. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol. 2024;21:743–61. https://doi.org/10.1038/s41571-024-00935-6.CrossRefPubMed
Lloyd MR, Jhaveri K, Kalinsky K, Bardia A, Wander SA. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol. 2024;21:743–61. https://doi.org/10.1038/s41571-024-00935-6.CrossRefPubMed
9.
go back to reference Hsu E, Arezo SM, Graff SL. Updates in systemic treatment of hormone receptor-positive early-stage breast cancer. Curr Treat Options Oncol. 2024;25:1323–34. https://doi.org/10.1007/s11864-024-01258-5.CrossRefPubMed
Hsu E, Arezo SM, Graff SL. Updates in systemic treatment of hormone receptor-positive early-stage breast cancer. Curr Treat Options Oncol. 2024;25:1323–34. https://doi.org/10.1007/s11864-024-01258-5.CrossRefPubMed
10.
go back to reference Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, et al. A Meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277–89. https://doi.org/10.1016/j.ejca.2013.10.004.CrossRefPubMed
Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, Adamoli L, Munzone E, Sciandivasci A, De Vita F, et al. A Meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277–89. https://doi.org/10.1016/j.ejca.2013.10.004.CrossRefPubMed
11.
go back to reference Goodman K, Abel MK, Lawhn-Heath C, Molina-Vega J, Jones EF, Mukhtar RA. Molecular imaging for estrogen receptor-positive breast cancer. Surg Oncol Clin N Am. 2022;31:569–79. https://doi.org/10.1016/j.soc.2022.06.001.CrossRefPubMedPubMedCentral
Goodman K, Abel MK, Lawhn-Heath C, Molina-Vega J, Jones EF, Mukhtar RA. Molecular imaging for estrogen receptor-positive breast cancer. Surg Oncol Clin N Am. 2022;31:569–79. https://doi.org/10.1016/j.soc.2022.06.001.CrossRefPubMedPubMedCentral
12.
go back to reference Ulaner GA, Fowler AM, Clark AS, Linden H. Estrogen receptor-targeted and progesterone receptor-targeted PET for patients with breast cancer. PET Clin. 2023;18:531–42. https://doi.org/10.1016/j.cpet.2023.04.008.CrossRefPubMed
Ulaner GA, Fowler AM, Clark AS, Linden H. Estrogen receptor-targeted and progesterone receptor-targeted PET for patients with breast cancer. PET Clin. 2023;18:531–42. https://doi.org/10.1016/j.cpet.2023.04.008.CrossRefPubMed
13.
go back to reference Zhou W, Franc BL, DeMartini WB, Rosen EL. Estrogen receptor-targeted PET imaging for breast cancer. Radiology. 2024;312:e240315. https://doi.org/10.1148/radiol.240315.CrossRefPubMed
Zhou W, Franc BL, DeMartini WB, Rosen EL. Estrogen receptor-targeted PET imaging for breast cancer. Radiology. 2024;312:e240315. https://doi.org/10.1148/radiol.240315.CrossRefPubMed
14.
go back to reference Mankoff D, Balogová S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, Van Kruchten M, Vaz SC, Fowler A, Linden H, et al. Summary: SNMMI procedure standard/EANM practice guideline for estrogen receptor imaging of patients with breast cancer using 16α-[18 F]Fluoro-17β-Estradiol PET. J Nucl Med. 2024;65:221–3. https://doi.org/10.2967/jnumed.123.266938.CrossRefPubMed
Mankoff D, Balogová S, Dunnwald L, Dehdashti F, DeVries E, Evangelista L, Van Kruchten M, Vaz SC, Fowler A, Linden H, et al. Summary: SNMMI procedure standard/EANM practice guideline for estrogen receptor imaging of patients with breast cancer using 16α-[18 F]Fluoro-17β-Estradiol PET. J Nucl Med. 2024;65:221–3. https://doi.org/10.2967/jnumed.123.266938.CrossRefPubMed
15.
go back to reference McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Research. 2021;23:6. https://doi.org/10.1186/s13058-020-01384-6.CrossRefPubMedPubMedCentral
McCart Reed AE, Kalinowski L, Simpson PT, Lakhani SR. Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. Breast Cancer Research. 2021;23:6. https://doi.org/10.1186/s13058-020-01384-6.CrossRefPubMedPubMedCentral
16.
go back to reference Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163:506–19. https://doi.org/10.1016/j.cell.2015.09.033.CrossRefPubMedPubMedCentral
Ciriello G, Gatza ML, Beck AH, Wilkerson MD, Rhie SK, Pastore A, Zhang H, McLellan M, Yau C, Kandoth C, et al. Comprehensive molecular portraits of invasive lobular breast cancer. Cell. 2015;163:506–19. https://doi.org/10.1016/j.cell.2015.09.033.CrossRefPubMedPubMedCentral
17.
go back to reference Bottoni G, Piccardo A, Fiz F, Siri G, Matteucci F, Rocca A, Nanni O, Monti M, Brain E, Alberini JL, et al. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. Eur J Radiol. 2021;141:109821. https://doi.org/10.1016/j.ejrad.2021.109821.CrossRefPubMed
Bottoni G, Piccardo A, Fiz F, Siri G, Matteucci F, Rocca A, Nanni O, Monti M, Brain E, Alberini JL, et al. Heterogeneity of bone metastases as an important prognostic factor in patients affected by oestrogen receptor-positive breast cancer. The role of combined [18F]Fluoroestradiol PET/CT and [18F]Fluorodeoxyglucose PET/CT. Eur J Radiol. 2021;141:109821. https://doi.org/10.1016/j.ejrad.2021.109821.CrossRefPubMed
18.
go back to reference Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA. Between-patient and within-patient (Site-to-Site) variability in estrogen receptor binding, measured in vivo by 18 F-Fluoroestradiol PET. J Nucl Med. 2011;52:1541–9. https://doi.org/10.2967/jnumed.111.091439.CrossRefPubMed
Kurland BF, Peterson LM, Lee JH, Linden HM, Schubert EK, Dunnwald LK, Link JM, Krohn KA, Mankoff DA. Between-patient and within-patient (Site-to-Site) variability in estrogen receptor binding, measured in vivo by 18 F-Fluoroestradiol PET. J Nucl Med. 2011;52:1541–9. https://doi.org/10.2967/jnumed.111.091439.CrossRefPubMed
19.
go back to reference Yang Z, Sun Y, Xue J, Yao Z, Xu J, Cheng J, Shi W, Zhu B, Zhang Y, Zhang Y. Can positron emission tomography/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer? ––a pilot study. PLoS ONE. 2013;8: e78192. https://doi.org/10.1371/journal.pone.0078192.CrossRefPubMedPubMedCentral
Yang Z, Sun Y, Xue J, Yao Z, Xu J, Cheng J, Shi W, Zhu B, Zhang Y, Zhang Y. Can positron emission tomography/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer? ––a pilot study. PLoS ONE. 2013;8: e78192. https://doi.org/10.1371/journal.pone.0078192.CrossRefPubMedPubMedCentral
20.
go back to reference Sun Y, Yang Z, Zhang Y, Xue J, Wang M, Shi W, Zhu B, Hu S, Yao Z, Pan H, et al. The preliminary study of 16α-[18F]Fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. PLoS ONE. 2015;10: e0116341. https://doi.org/10.1371/journal.pone.0116341.CrossRefPubMedPubMedCentral
Sun Y, Yang Z, Zhang Y, Xue J, Wang M, Shi W, Zhu B, Hu S, Yao Z, Pan H, et al. The preliminary study of 16α-[18F]Fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. PLoS ONE. 2015;10: e0116341. https://doi.org/10.1371/journal.pone.0116341.CrossRefPubMedPubMedCentral
21.
go back to reference Gupta M, Datta A, Choudhury P, Dsouza M, Batra U, Mishra A. Can 18F-Fluoroestradiol positron emission tomography become a new imaging standard in the estrogen receptor-positive breast cancer patient: a prospective comparative study with 18F-fluorodeoxyglucose positron emission tomography? World J Nucl Med. 2017;16:133–9. https://doi.org/10.4103/1450-1147.203071.CrossRefPubMedPubMedCentral
Gupta M, Datta A, Choudhury P, Dsouza M, Batra U, Mishra A. Can 18F-Fluoroestradiol positron emission tomography become a new imaging standard in the estrogen receptor-positive breast cancer patient: a prospective comparative study with 18F-fluorodeoxyglucose positron emission tomography? World J Nucl Med. 2017;16:133–9. https://doi.org/10.4103/1450-1147.203071.CrossRefPubMedPubMedCentral
22.
go back to reference Yang Z, Sun Y, Xu X, Zhang Y, Zhang J, Xue J, Wang M, Yuan H, Hu S, Shi W, et al. The assessment of estrogen receptor status and its intratumoral heterogeneity in patients with breast cancer by using 18f-fluoroestradiol PET/CT. Clin Nucl Med. 2017;42:421–7. https://doi.org/10.1097/RLU.0000000000001587.CrossRefPubMed
Yang Z, Sun Y, Xu X, Zhang Y, Zhang J, Xue J, Wang M, Yuan H, Hu S, Shi W, et al. The assessment of estrogen receptor status and its intratumoral heterogeneity in patients with breast cancer by using 18f-fluoroestradiol PET/CT. Clin Nucl Med. 2017;42:421–7. https://doi.org/10.1097/RLU.0000000000001587.CrossRefPubMed
23.
go back to reference Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM. Estrogen receptor binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res. 2017;23:407–15. https://doi.org/10.1158/1078-0432.CCR-16-0362.CrossRefPubMed
Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM. Estrogen receptor binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res. 2017;23:407–15. https://doi.org/10.1158/1078-0432.CCR-16-0362.CrossRefPubMed
24.
go back to reference Liu C, Gong C, Liu S, Zhang Y, Zhang Y, Xu X, Yuan H, Wang B, Yang Z. 18F-FES PET/CT influences the staging and management of patients with newly diagnosed estrogen receptor-positive breast cancer: a retrospective comparative study with 18F-FDG PET/CT. Oncologist. 2019;24:e1277–85. https://doi.org/10.1634/theoncologist.2019-0096.CrossRefPubMedPubMedCentral
Liu C, Gong C, Liu S, Zhang Y, Zhang Y, Xu X, Yuan H, Wang B, Yang Z. 18F-FES PET/CT influences the staging and management of patients with newly diagnosed estrogen receptor-positive breast cancer: a retrospective comparative study with 18F-FDG PET/CT. Oncologist. 2019;24:e1277–85. https://doi.org/10.1634/theoncologist.2019-0096.CrossRefPubMedPubMedCentral
25.
go back to reference Boers J, Venema CM, de Vries EFJ, Glaudemans AWJM, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Eur J Cancer. 2020;126:11–20. https://doi.org/10.1016/j.ejca.2019.10.024.CrossRefPubMed
Boers J, Venema CM, de Vries EFJ, Glaudemans AWJM, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Eur J Cancer. 2020;126:11–20. https://doi.org/10.1016/j.ejca.2019.10.024.CrossRefPubMed
26.
go back to reference Liu C, Xu X, Yuan H, Zhang Y, Zhang Y, Song S, Yang Z. Dual tracers of 16α-[18F]Fluoro-17β-Estradiol and [18F]Fluorodeoxyglucose for prediction of progression-free survival after fulvestrant therapy in patients with HR+/HER2- metastatic breast cancer. Front Oncol. 2020;10:580277. https://doi.org/10.3389/fonc.2020.580277.CrossRefPubMedPubMedCentral
Liu C, Xu X, Yuan H, Zhang Y, Zhang Y, Song S, Yang Z. Dual tracers of 16α-[18F]Fluoro-17β-Estradiol and [18F]Fluorodeoxyglucose for prediction of progression-free survival after fulvestrant therapy in patients with HR+/HER2- metastatic breast cancer. Front Oncol. 2020;10:580277. https://doi.org/10.3389/fonc.2020.580277.CrossRefPubMedPubMedCentral
27.
go back to reference Chae SY, Son HJ, Lee DY, Shin E, Oh JS, Seo SY, Baek S, Kim JY, Na SJ, Moon DH. Comparison of diagnostic sensitivity of [18F]Fluoroestradiol and [18F]Fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. EJNMMI Res. 2020;10:54. https://doi.org/10.1186/s13550-020-00643-z.CrossRefPubMedPubMedCentral
Chae SY, Son HJ, Lee DY, Shin E, Oh JS, Seo SY, Baek S, Kim JY, Na SJ, Moon DH. Comparison of diagnostic sensitivity of [18F]Fluoroestradiol and [18F]Fluorodeoxyglucose positron emission tomography/computed tomography for breast cancer recurrence in patients with a history of estrogen receptor-positive primary breast cancer. EJNMMI Res. 2020;10:54. https://doi.org/10.1186/s13550-020-00643-z.CrossRefPubMedPubMedCentral
28.
go back to reference Peterson LM, Kurland BF, Yan F, Jiresova AN, Gadi VK, Specht JM, Gralow JR, Schubert EK, Link JM, Krohn KA, et al. F-Fluoroestradiol PET imaging in a phase II Trial of Vorinostat to restore endocrine sensitivity in ER+/HER2− metastatic breast cancer. Journal of Nuclear Medicine. 2021;62:184–90. https://doi.org/10.2967/jnumed.120.244459.CrossRefPubMedPubMedCentral
Peterson LM, Kurland BF, Yan F, Jiresova AN, Gadi VK, Specht JM, Gralow JR, Schubert EK, Link JM, Krohn KA, et al. F-Fluoroestradiol PET imaging in a phase II Trial of Vorinostat to restore endocrine sensitivity in ER+/HER2− metastatic breast cancer. Journal of Nuclear Medicine. 2021;62:184–90. https://doi.org/10.2967/jnumed.120.244459.CrossRefPubMedPubMedCentral
29.
go back to reference Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A. Head-to-head evaluation of 18 F-FES and 18 F-FDG PET/CT in metastatic invasive lobular breast cancer. J Nucl Med. 2021;62:326–31. https://doi.org/10.2967/jnumed.120.247882.CrossRefPubMedPubMedCentral
Ulaner GA, Jhaveri K, Chandarlapaty S, Hatzoglou V, Riedl CC, Lewis JS, Mauguen A. Head-to-head evaluation of 18 F-FES and 18 F-FDG PET/CT in metastatic invasive lobular breast cancer. J Nucl Med. 2021;62:326–31. https://doi.org/10.2967/jnumed.120.247882.CrossRefPubMedPubMedCentral
30.
go back to reference Liu C, Ma G, Zhang J, Cheng J, Yang Z, Song S. 18F-FES and 18F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with endocrine treatment. Ann Nucl Med. 2023;37:675–84. https://doi.org/10.1007/s12149-023-01871-8.CrossRefPubMed
Liu C, Ma G, Zhang J, Cheng J, Yang Z, Song S. 18F-FES and 18F-FDG PET/CT imaging as a predictive biomarkers for metastatic breast cancer patients undergoing cyclin-dependent 4/6 kinase inhibitors with endocrine treatment. Ann Nucl Med. 2023;37:675–84. https://doi.org/10.1007/s12149-023-01871-8.CrossRefPubMed
31.
go back to reference Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C, et al. Prospective pilot study of 18 F-Fluoroestradiol PET/CT in patients with invasive lobular carcinomas. Am J Roentgenol. 2023;221:228–39. https://doi.org/10.2214/AJR.22.28809.CrossRef
Covington MF, Hoffman JM, Morton KA, Buckway B, Boucher KM, Rosenthal RE, Porretta JM, Brownson KE, Matsen CB, Vaklavas C, et al. Prospective pilot study of 18 F-Fluoroestradiol PET/CT in patients with invasive lobular carcinomas. Am J Roentgenol. 2023;221:228–39. https://doi.org/10.2214/AJR.22.28809.CrossRef
32.
go back to reference Bottoni G, Fiz F, Puntoni M, Matteucci F, Monti M, DeCensi A, Nanni O, Brain E, Alberini JL, Dib B, et al. Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study. Eur J Nucl Med Mol Imaging. 2023;50:2477–85. https://doi.org/10.1007/s00259-023-06173-9.CrossRefPubMed
Bottoni G, Fiz F, Puntoni M, Matteucci F, Monti M, DeCensi A, Nanni O, Brain E, Alberini JL, Dib B, et al. Diagnostic effectiveness of [18F]Fluoroestradiol PET/CT in oestrogen receptor-positive breast cancer: the key role of histopathology. Evidence from an international multicentre prospective study. Eur J Nucl Med Mol Imaging. 2023;50:2477–85. https://doi.org/10.1007/s00259-023-06173-9.CrossRefPubMed
33.
go back to reference Iqbal R, Yaqub M, Bektas HO, Oprea-Lager DE, de Vries EGE, Glaudemans AWJM, Aftimos P, Gebhart G, Beelen AP, Schuit RC, et al. [18F]FDG and [18F]FES PET/CT imaging as a biomarker for therapy effect in patients with metastatic ER+ Breast cancer undergoing treatment with rintodestrant. Clin Cancer Res. 2023;29:2075–84. https://doi.org/10.1158/1078-0432.CCR-22-2720.CrossRefPubMed
Iqbal R, Yaqub M, Bektas HO, Oprea-Lager DE, de Vries EGE, Glaudemans AWJM, Aftimos P, Gebhart G, Beelen AP, Schuit RC, et al. [18F]FDG and [18F]FES PET/CT imaging as a biomarker for therapy effect in patients with metastatic ER+ Breast cancer undergoing treatment with rintodestrant. Clin Cancer Res. 2023;29:2075–84. https://doi.org/10.1158/1078-0432.CCR-22-2720.CrossRefPubMed
34.
go back to reference Kiatkittikul P, Mayurasakorn S, Promteangtrong C, Kunawudhi A, Siripongsatian D, Hirata N, Jantarato A, Boonkawin N, Yaset S, Kongsakorn P, et al. Head-to-Head comparison of 18F-FDG and 18F-FES PET/CT for initial staging of ER-positive breast cancer patients. Eur J Hybrid Imaging. 2023;7:23. https://doi.org/10.1186/s41824-023-00176-3.CrossRefPubMedPubMedCentral
Kiatkittikul P, Mayurasakorn S, Promteangtrong C, Kunawudhi A, Siripongsatian D, Hirata N, Jantarato A, Boonkawin N, Yaset S, Kongsakorn P, et al. Head-to-Head comparison of 18F-FDG and 18F-FES PET/CT for initial staging of ER-positive breast cancer patients. Eur J Hybrid Imaging. 2023;7:23. https://doi.org/10.1186/s41824-023-00176-3.CrossRefPubMedPubMedCentral
35.
go back to reference Liu C, Ma G, Xu X, Song S, Yang Z. Can 18F-FES PET improve the evaluation of 18F-FDG PET in patients with metastatic invasive lobular carcinoma? Clin Nucl Med. 2024;49:301–7. https://doi.org/10.1097/RLU.0000000000005085.CrossRefPubMed
Liu C, Ma G, Xu X, Song S, Yang Z. Can 18F-FES PET improve the evaluation of 18F-FDG PET in patients with metastatic invasive lobular carcinoma? Clin Nucl Med. 2024;49:301–7. https://doi.org/10.1097/RLU.0000000000005085.CrossRefPubMed
36.
go back to reference van Geel JJL, Moustaquim J, Boers J, Elias SG, Smeets EMM, Knip JJ, Glaudemans AWJM, de Vries EFJ, Hospers GAP, van Kruchten M, et al. Intrapatient 16α-[18 F]Fluoro-17β-Estradiol PET heterogeneity as a prognostic factor for endocrine therapy response and survival in patients with estrogen receptor-positive metastatic breast cancer. J Nucl Med. 2025;66:194–200. https://doi.org/10.2967/jnumed.124.268984.CrossRefPubMed
van Geel JJL, Moustaquim J, Boers J, Elias SG, Smeets EMM, Knip JJ, Glaudemans AWJM, de Vries EFJ, Hospers GAP, van Kruchten M, et al. Intrapatient 16α-[18 F]Fluoro-17β-Estradiol PET heterogeneity as a prognostic factor for endocrine therapy response and survival in patients with estrogen receptor-positive metastatic breast cancer. J Nucl Med. 2025;66:194–200. https://doi.org/10.2967/jnumed.124.268984.CrossRefPubMed
37.
go back to reference Garrido P, Morán J, Alonso A, González S, González C. 17β-Estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 Cells. Endocrinology. 2013;154:1979–89. https://doi.org/10.1210/en.2012-1558.CrossRefPubMed
Garrido P, Morán J, Alonso A, González S, González C. 17β-Estradiol activates glucose uptake via GLUT4 translocation and PI3K/Akt signaling pathway in MCF-7 Cells. Endocrinology. 2013;154:1979–89. https://doi.org/10.1210/en.2012-1558.CrossRefPubMed
38.
go back to reference Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104:1828–35. https://doi.org/10.1038/bjc.2011.156.CrossRefPubMedPubMedCentral
Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104:1828–35. https://doi.org/10.1038/bjc.2011.156.CrossRefPubMedPubMedCentral
39.
go back to reference Xie Y, Du X, Zhao Y, Gong C, Hu S, You S, Song S, Hu X, Yang Z, Wang B. Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET. Cancers (Basel). 2022;14:3531. https://doi.org/10.3390/cancers14143531.CrossRefPubMed
Xie Y, Du X, Zhao Y, Gong C, Hu S, You S, Song S, Hu X, Yang Z, Wang B. Chemotherapy Shows a Better Efficacy Than Endocrine Therapy in Metastatic Breast Cancer Patients with a Heterogeneous Estrogen Receptor Expression Assessed by 18F-FES PET. Cancers (Basel). 2022;14:3531. https://doi.org/10.3390/cancers14143531.CrossRefPubMed
40.
go back to reference Zinger L, Merenbakh-Lamin K, Klein A, Elazar A, Journo S, Boldes T, Pasmanik-Chor M, Spitzer A, Rubinek T, Wolf I. Ligand-binding domain-activating mutations of ESR1 rewire cellular metabolism of breast cancer cells. Clin Cancer Res. 2019;25:2900–14. https://doi.org/10.1158/1078-0432.CCR-18-1505.CrossRefPubMed
Zinger L, Merenbakh-Lamin K, Klein A, Elazar A, Journo S, Boldes T, Pasmanik-Chor M, Spitzer A, Rubinek T, Wolf I. Ligand-binding domain-activating mutations of ESR1 rewire cellular metabolism of breast cancer cells. Clin Cancer Res. 2019;25:2900–14. https://doi.org/10.1158/1078-0432.CCR-18-1505.CrossRefPubMed
41.
go back to reference Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17–31. https://doi.org/10.1007/s00259-017-3740-2.CrossRefPubMedPubMedCentral
Aide N, Lasnon C, Veit-Haibach P, Sera T, Sattler B, Boellaard R. EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies. Eur J Nucl Med Mol Imaging. 2017;44:17–31. https://doi.org/10.1007/s00259-017-3740-2.CrossRefPubMedPubMedCentral
42.
go back to reference Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed
Boellaard R, Delgado-Bolton R, Oyen WJG, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–54. https://doi.org/10.1007/s00259-014-2961-x.CrossRefPubMed
Metadata
- Title
- Head-to-Head comparison of [18F]FES and [18F]FDG PET/CT in breast cancer patients: has a new era come?
- Authors
-
Priscilla Guglielmo
Rosario Mazzola
Shadya Sara Darwish
Francesco Valenti
Tommaso Martino De Pas
Lucia Setti
Manuela Bonacina
Massimo Maria Grassi
Laura Evangelista
- Publication date
- 11-03-2025
- Publisher
- Springer Berlin Heidelberg
- Published in
-
European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089 - DOI
- https://doi.org/10.1007/s00259-025-07186-2